NCT03997929View on ClinicalTrials.gov

Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients (pBDG2)

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

January 20, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

February 7, 2023

Conditions
Intra Abdominal InfectionsCandidiasis, InvasivePeritoneal CandidiasisCritically Ill
Interventions
DIAGNOSTIC_TEST

1.3 BETA D GLUCAN

dosage of 1.3 BETA D GLUCAN in the peritoneal fluid obtained during surgery with the β-glucan test (Fujifilm Wako Chemicals, Osaka, Japan)

Trial Locations (4)

21079

BOUHEMAD Belaid, Dijon

25030

PILI-FLOURY Sebastien, Besançon

57000

CHR Mercy, Metz

67098

POTTECHER Julien, Strasbourg

All Listed Sponsors
lead

Central Hospital, Nancy, France

OTHER

NCT03997929 - Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients (pBDG2) | Biotech Hunter | Biotech Hunter